Abstract: Objective To compare the curative effect and toxicities of oxaliplatin combined with S-1 (SOX) and gemcitabine combined with cisplatin (GP) on advanced triple-negative breast cancer(TNBC) patients. Methods Advanced TNBC patients randomly accepted several cycles of SOX regimen(SOX) (n=63) and GP regimen(GP) (n=57). The efficacy and toxicity were observed between two regimens. Results The total response rates (RR) were 34.9% in SOX group and 35.1% in GP group. The disease control rates(DCR) were 68.3% in SOX group and 70.2% in GP group, respectively (P>0.05); the median time to progression were 9.5 months in SOX group and 8.1 months in GP group (P=0.033); 1-year survival rates were 69.8% and 63.2%, and the overall survival(OS) was 19.5 and 18.7 months, respectively, without any statistically significant difference (P=0.554, 0.207). Adverse reactions were similar between the two groups. The incidence of diarrhea, liver function damage, peripheral nerve toxicity and hand-foot syndrome in SOX group were greater than those in GP group; the incidence of thrombocytopenia, nausea/vomiting, renal toxicity and skin rash in GP group were greater than those in SOX group (P<0.05). Conclusion Both SOX and GP regimens are safe, effective and tolerable in treating advanced TNBC patients.